Gonzalo N Olaverria Salavaggione
Overview
Explore the profile of Gonzalo N Olaverria Salavaggione including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
48
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McMichael E, Benner B, Atwal L, Courtney N, Mo X, Davis M, et al.
Clin Cancer Res
. 2019 May;
25(16):4955-4965.
PMID: 31142501
Purpose: mAbs including cetuximab can induce antibody-dependent cellular cytotoxicity (ADCC) and cytokine production mediated via innate immune cells with the ability to recognize mAb-coated tumors. Preclinical modeling has shown that...
2.
Duggan M, Regan-Fendt K, Olaverria Salavaggione G, Howard J, Stiff A, Sabella J, et al.
Melanoma Res
. 2019 May;
29(5):491-500.
PMID: 31116161
Neuroblastoma RAS viral oncogene homolog is a commonly mutated oncogene in melanoma, and therapeutic targeting of neuroblastoma RAS viral oncogene homolog has proven difficult. We characterized the expression and phenotypic...
3.
Olaverria Salavaggione G, Duggan M, Carson W
Melanoma Res
. 2018 Jul;
28(5):390-397.
PMID: 30020196
The NEDD8 pathway is a known activator of the ubiquitin-protease system, a complex that is partially responsible for the degradation of proteins involved in cell-cycle regulation and neoplastic growth. In...
4.
Duggan M, Stiff A, Bainazar M, Regan K, Olaverria Salavaggione G, Maharry S, et al.
Proc Natl Acad Sci U S A
. 2017 Aug;
114(36):9629-9634.
PMID: 28827320
Activating mutations in BRAF are found in 50% of melanomas and although treatment with BRAF inhibitors (BRAFi) is effective, resistance often develops. We now show that recently discovered NRAS isoform...